College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy

The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban

Michael Laposata, David Green, Elizabeth M. Van Cott, Trevor W. Barrowcliffe, Scott H. Goodnight, Randolph C. Sosolik

Research output: Contribution to journalArticle

219 Citations (Scopus)

Abstract

Objective.-To review the role of the laboratory in monitoring therapy with low-molecular-weight heparin, danaparoid, hirudin, and argatroban, as reflected in the medical literature and the consensus opinion of recognized experts in the field. Data Sources.-Review of the medical literature and current clinical practice by a panel of 6 international experts in the field of anticoagulant therapy. Data Extraction and Synthesis.-The experts made an extensive review of the published literature and prepared a draft manuscript, which included preliminary recommendations. The draft manuscript was circulated to participants in the College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy prior to the conference. The manuscript and recommendations were then presented at the Conference for discussion. Recommendations were accepted if a consensus of the 26 experts attending the Conference was reached. The results of the discussion were used to revise the manuscript into its final form. Conclusions.-This report reviews the mechanism of action and potential uses of these newer anticoagulant agents. General guidelines for monitoring these agents and 9 specific recommendations for laboratory monitoring of low- molecular-weight heparin and danaparoid are provided, along with citation of the appropriate supporting literature. Issues for which a consensus was not reached at the Conference are also discussed.

Original languageEnglish (US)
Pages (from-to)799-807
Number of pages9
JournalArchives of Pathology and Laboratory Medicine
Volume122
Issue number9
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Hirudins
Manuscripts
Low Molecular Weight Heparin
Anticoagulants
Information Storage and Retrieval
Expert Testimony
Therapeutics
Action Potentials
Guidelines
argatroban
Pathologists
danaproid

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy : The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. / Laposata, Michael; Green, David; Van Cott, Elizabeth M.; Barrowcliffe, Trevor W.; Goodnight, Scott H.; Sosolik, Randolph C.

In: Archives of Pathology and Laboratory Medicine, Vol. 122, No. 9, 09.1998, p. 799-807.

Research output: Contribution to journalArticle

@article{1cc93be6e06643b382a270a102375cda,
title = "College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban",
abstract = "Objective.-To review the role of the laboratory in monitoring therapy with low-molecular-weight heparin, danaparoid, hirudin, and argatroban, as reflected in the medical literature and the consensus opinion of recognized experts in the field. Data Sources.-Review of the medical literature and current clinical practice by a panel of 6 international experts in the field of anticoagulant therapy. Data Extraction and Synthesis.-The experts made an extensive review of the published literature and prepared a draft manuscript, which included preliminary recommendations. The draft manuscript was circulated to participants in the College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy prior to the conference. The manuscript and recommendations were then presented at the Conference for discussion. Recommendations were accepted if a consensus of the 26 experts attending the Conference was reached. The results of the discussion were used to revise the manuscript into its final form. Conclusions.-This report reviews the mechanism of action and potential uses of these newer anticoagulant agents. General guidelines for monitoring these agents and 9 specific recommendations for laboratory monitoring of low- molecular-weight heparin and danaparoid are provided, along with citation of the appropriate supporting literature. Issues for which a consensus was not reached at the Conference are also discussed.",
author = "Michael Laposata and David Green and {Van Cott}, {Elizabeth M.} and Barrowcliffe, {Trevor W.} and Goodnight, {Scott H.} and Sosolik, {Randolph C.}",
year = "1998",
month = "9",
language = "English (US)",
volume = "122",
pages = "799--807",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "9",

}

TY - JOUR

T1 - College of American pathologists conference XXXI on laboratory monitoring of anticoagulant therapy

T2 - The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban

AU - Laposata, Michael

AU - Green, David

AU - Van Cott, Elizabeth M.

AU - Barrowcliffe, Trevor W.

AU - Goodnight, Scott H.

AU - Sosolik, Randolph C.

PY - 1998/9

Y1 - 1998/9

N2 - Objective.-To review the role of the laboratory in monitoring therapy with low-molecular-weight heparin, danaparoid, hirudin, and argatroban, as reflected in the medical literature and the consensus opinion of recognized experts in the field. Data Sources.-Review of the medical literature and current clinical practice by a panel of 6 international experts in the field of anticoagulant therapy. Data Extraction and Synthesis.-The experts made an extensive review of the published literature and prepared a draft manuscript, which included preliminary recommendations. The draft manuscript was circulated to participants in the College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy prior to the conference. The manuscript and recommendations were then presented at the Conference for discussion. Recommendations were accepted if a consensus of the 26 experts attending the Conference was reached. The results of the discussion were used to revise the manuscript into its final form. Conclusions.-This report reviews the mechanism of action and potential uses of these newer anticoagulant agents. General guidelines for monitoring these agents and 9 specific recommendations for laboratory monitoring of low- molecular-weight heparin and danaparoid are provided, along with citation of the appropriate supporting literature. Issues for which a consensus was not reached at the Conference are also discussed.

AB - Objective.-To review the role of the laboratory in monitoring therapy with low-molecular-weight heparin, danaparoid, hirudin, and argatroban, as reflected in the medical literature and the consensus opinion of recognized experts in the field. Data Sources.-Review of the medical literature and current clinical practice by a panel of 6 international experts in the field of anticoagulant therapy. Data Extraction and Synthesis.-The experts made an extensive review of the published literature and prepared a draft manuscript, which included preliminary recommendations. The draft manuscript was circulated to participants in the College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy prior to the conference. The manuscript and recommendations were then presented at the Conference for discussion. Recommendations were accepted if a consensus of the 26 experts attending the Conference was reached. The results of the discussion were used to revise the manuscript into its final form. Conclusions.-This report reviews the mechanism of action and potential uses of these newer anticoagulant agents. General guidelines for monitoring these agents and 9 specific recommendations for laboratory monitoring of low- molecular-weight heparin and danaparoid are provided, along with citation of the appropriate supporting literature. Issues for which a consensus was not reached at the Conference are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=0031680310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031680310&partnerID=8YFLogxK

M3 - Article

VL - 122

SP - 799

EP - 807

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 9

ER -